Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

(2010) J. J. Neumiller et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

(2010) Hisko Oeseburg et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

(2010) Que Liu et al.   Cardiovascular Diabetology

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

(2010) L Romayne Kurukulasuriya et al.   Cardiovascular Diabetology

Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

(2010) Barbara Huisamen et al.   CARDIOVASCULAR DRUGS AND THERAPY

Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure

(2010) B. Daan Westenbrink et al.   CARDIOVASCULAR RESEARCH

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control

(2010) P. Anagnostis et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats

(2010) X. Wang et al.   XENOBIOTICA

Effect of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor (Vildagliptin) on Peripheral Nerves in Streptozotocin-induced Diabetic Rats

(2009) Heung Yong Jin et al.   ARCHIVES OF MEDICAL RESEARCH

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease

(2009) Enrique Z Fisman et al.   Cardiovascular Diabetology

Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

(2009) E.J. Verspohl   PHARMACOLOGY & THERAPEUTICS

DPP4 Inhibitors: a new approach in diabetes treatment

(2008) John Doupis et al.   ADVANCES IN THERAPY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

(2008) Indu Poornima et al.   Circulation-Heart Failure

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

(2007) David P. Sonne et al.   REGULATORY PEPTIDES